NasdaqGS:ZBIOBiotechs
Assessing Zenas BioPharma (ZBIO) Valuation After US$300 Million Equity And Convertible Notes Financing
Zenas BioPharma (ZBIO) has just raised fresh capital through a twin financing, completing a US$100 million follow on common stock offering at US$20 per share and a US$200 million 2.50% convertible notes issue due 2032.
See our latest analysis for Zenas BioPharma.
The fresh capital raise comes after a mixed stretch for the stock, with a 29.2% 90 day share price return contrasting with a 15.1% 1 month share price decline, while the 1 year total shareholder return of 178.3% points to strong...